The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Pimicotinib in tenosynovial giant cell tumor (TGCT): Efficacy, safety and patient-reported outcomes of phase 3 MANEUVER study.
 
Xiaohui Niu
No Relationships to Disclose
 
Vinod Ravi
Stock and Other Ownership Interests - AstraZeneca; Merck; Moderna Therapeutics; Pfizer; TRACON Pharma
Honoraria - UpToDate
Consulting or Advisory Role - AADi; Daiichi Sankyo; Daiichi Sankyo; Deciphera; Deciphera; Gerson Lehrman Group; Guidepoint Inc
Research Funding - AADi (Inst); Athenex (Inst); Deciphera (Inst); Ikena Oncology (Inst); Ikena Oncology (Inst); Novartis (Inst); TRACON Pharma (Inst)
Patents, Royalties, Other Intellectual Property - Author Royalties from Uptodate
Travel, Accommodations, Expenses - Daiichi Sankyo
 
Javier Martin Broto
Leadership - Sarcoma Research Solutions SL
Consulting or Advisory Role - Amgen; Asofarma; Bayer; Boehringer Ingelheim; GlaxoSmithKline; Lilly; Novartis; PharmaMar; Roche; Tecnofarma
Speakers' Bureau - PharmaMar
Research Funding - Adaptimmune; Amgen (Inst); Arog (Inst); Ayala Pharmaceuticals (Inst); Bayer (Inst); Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); CEBIOTEX (Inst); Celgene (Inst); Daiichi Sankyo (Inst); Deciphera (Inst); Eisai; Eisai (Inst); FORMA Therapeutics (Inst); GlaxoSmithKline (Inst); Immix BioPharma (Inst); InhibRx (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Lixte Biotechnology (Inst); Nektar (Inst); Novartis; Novartis (Inst); Pfizer (Inst); PharmaMar; PharmaMar (Inst); Philogen (Inst); PTC Therapeutics (Inst); Rain Therapeutics (Inst); SpringWorks Therapeutics (Inst)
Expert Testimony - Novartis; PharmaMar
Travel, Accommodations, Expenses - Pfizer; PharmaMar
 
Yong Zhou
Speakers' Bureau - BeiGene
Research Funding - Abbisko Therapeutics Co., Ltd.
 
Albiruni Abdul Razak
Consulting or Advisory Role - Alexion Pharmaceuticals; Boehringer Ingelheim; Clinical Research Malaysia; Inhibrx; Medison; UpToDate
Research Funding - 23 and Me; Abbisko Therapeutics (Inst); Abbvie; Adaptimmune; Amgen; AstraZeneca (Inst); Boehringer Ingelheim; Bristol-Myers Squibb; Cogent Biosciences (Inst); Daiichi Sankyo; Deciphera; Frontier Therapeutics; Gilead Sciences (Inst); GlaxoSmithKline; Intensity Therapeutics (Inst); Iterion Therapeutics; Karyopharm Therapeutics; Kelun (Inst); Merck; Neoleukin Therapeutics; Pfizer; Polaris (Inst); Rain Therapeutics; Roche/Genentech; Symphogen
Expert Testimony - Medison
 
Ramy Saleh
No Relationships to Disclose
 
Jingnan Shen
No Relationships to Disclose
 
Tang Liu
No Relationships to Disclose
 
Silvia Stacchiotti
Honoraria - Boehringer Ingelheim; Gentili; GlaxoSmithKline; PharmaMar; Servier
Consulting or Advisory Role - Agenus; Bayer; Boehringer Ingelheim; Daiichi Sankyo; deciphera; GlaxoSmithKline; Ikena Oncology; Ipsen; NEC OncoImmunity AS; Pharmaessentia; Regeneron; SERVIER
Research Funding - Abbisko Therapeutics (Inst); Advenchen Laboratories (Inst); Amgen (Inst); Ayala Pharmaceuticals (Inst); Bayer (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Daiichi Sankyo (Inst); Deciphera (Inst); Epizyme (Inst); GlaxoSmithKline (Inst); Hutchison MediPharma (Inst); InhibRx (Inst); Karyopharm Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst); Rain Therapeutics (Inst); SpringWorks Therapeutics (Inst)
Travel, Accommodations, Expenses - PharmaMar
 
Kamalesh Sankhala
No Relationships to Disclose
 
César Serrano
Honoraria - Deciphera; Roche
Consulting or Advisory Role - Blueprint Medicines; Cogent Biosciences; Deciphera; IDRX; NewBay Pharma
Research Funding - IDRX (Inst)
Travel, Accommodations, Expenses - Bayer; Gilead Sciences; Pfizer; PharmaMar
 
Jing Wang
No Relationships to Disclose
 
Yingqi Hua
No Relationships to Disclose
 
Piotr Rutkowski
Honoraria - Bristol-Myers Squibb; Genesis Pharma; Medison; Merck; MSD; Novartis; Pfizer; Pierre Fabre; Sanofi
Consulting or Advisory Role - Amgen; AstraZeneca; Blueprint Medicines; Bristol-Myers Squibb; MSD; Novartis; Philogen; Pierre Fabre
Speakers' Bureau - Novartis; Pfizer; Pierre Fabre
Research Funding - Bristol-Myers Squibb (Inst); Novartis (Inst); Pierre Fabre (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Orphan Europe; Pierre Fabre
 
Xiaojing Zhang
No Relationships to Disclose
 
Yi Feng
No Relationships to Disclose
 
Tao Li
No Relationships to Disclose
 
Giacomo Baldi
Honoraria - Eisai; GlaxoSmithKline; Lilly; MSD; PharmaMar
Consulting or Advisory Role - Aboutevents Srl; Boehringer Ingelheim; Eisai; Lilly; MSD; PharmaMar
Travel, Accommodations, Expenses - Lilly; Novartis; PharmaMar
 
Hairong Xu
No Relationships to Disclose
 
Hans Gelderblom
Research Funding - Abbisko Therapeutics (Inst); AmmaxBio (Inst); Blueprint Medicines (Inst); Deciphera (Inst); InhibRx (Inst); Ipsen (Inst); SynOX (Inst)
Travel, Accommodations, Expenses - Abbisko Therapeutics (Inst); Merck (Inst)